
Axsome Therapeutics reported on Monday that its Phase 3 study of its experimental depression drug missed its main trial goal. …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

